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Vaccines have had an unquestionable impact on public health during the last century. The most likely reason for 
the success of vaccines is the robust protective properties of specific antibodies. However, antibodies exert a strong 
selective pressure and many microorganisms, such as the obligatory intracellular parasite Trypanosoma cruzi, have 
been selected to survive in their presence. Although the host develops a strong immune response to T. cruzi, they 
do not clear the infection and instead progress to the chronic phase of the disease. Parasite persistence during the 
chronic phase of infection is now considered the main factor contributing to the chronic symptoms of the disease. 
Based on this finding, containment of parasite growth and survival may be one method to avoid the immunopathology 
of the chronic phase. In this context, vaccinologists have looked over the past 20 years for other immune effector 
mechanisms that could eliminate these antibody-resistant pathogens. We and others have tested the hypothesis that 
non-antibody-mediated cellular immune responses (CD4+ Th1 and CD8+ Tc1 cells) to specific parasite antigens/
genes expressed by T. cruzi could indeed be used for the purpose of vaccination. This hypothesis was confirmed in 
different mouse models, indicating a possible path for vaccine development.
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The population at risk of infection with obligatory 
intracellular parasites is estimated to be in the billions 
in individuals living in tropical and subtropical regions 
of the world where these parasites are endemic. Al-
though the pattern of disease transmission, infection 
and mortality caused by these parasites has continued 
to change over the past 100 years, the global burden of 
disease is greater than it has ever been. In developing 
countries, the circumstances supporting disease trans-
mission are unlikely to improve in the next 10 years. In 
light of these problems, it is essential to develop new 
strategies for the prevention and control of these dis-
eases. Also, given that global warming will increase, 
we can anticipate that invertebrate hosts will occupy 
greater areas of the world and possibly increase trans-
mission of insect-borne diseases.
Mass human vaccination against parasitic infection 
is currently not available. However, the first vaccine 
against human malaria is scheduled to become com-
mercially available in 2010. Research in this field is con-
sidered to be important because in the future, vaccines 
may complement other strategies such as chemotherapy 
or vector control for the prevention and control of these 
parasitic diseases. As a result, immuno-parasitologists 
have been researching the mechanisms of host-protective 
immunity and its target antigens for the last 30 years.
In spite of the unquestionable impact of vaccination 
on public health during the last century, only two dozen 
vaccines are routinely used today. Mechanistically, we 
do not know how most vaccines provide pre-immunity. 
The most likely reason for the success of these vaccines 
is the robust protective properties of specific antibodies. 
In fact, the efficacy of commercial vaccines has always 
been measured as a function of the antibody immune re-
sponse. Because antibodies are indeed so powerful, they 
exert a strong selective pressure on microorganisms. 
As expected, many microorganisms have been selected 
to survive in the presence of antibodies and ultimately 
use this selection to their advantage. Therefore, in many 
cases, the “robust” power of specific antibodies is not 
sufficient to eliminate the pathogen. In this context, over 
the last 25 years, vaccinologists have looked for other 
effector mechanisms that could either complement anti-
bodies or act independently to eliminate these antibody-
resistant pathogens.
The obligatory intracellular parasite Trypanosoma 
cruzi is responsible for the infection of millions of indi-
viduals across the Americas. Although hosts develop a 
strong immune response to T. cruzi, they do not clear the 
infection and instead progress to the chronic phase of the 
disease. Parasite persistence during the chronic phase of 
infection is now considered to be the main factor con-
tributing to the chronic symptoms of the disease. Based 
on this finding, containment of parasite growth and sur-
vival may be the best route to avoiding chronic phase 
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immunopathology. Prophylactic vaccination would help 
to reduce or completely eliminate the parasite burden, 
and thus represents a desirable method to restrict the de-
velopment of chronic symptoms of the disease.
In the past, vaccination studies have failed because 
researchers have in most cases focused on inducing pro-
tective antibodies. Essentially, these studies confirmed 
that antibodies alone are unable to completely eliminate 
the parasites and that the antigens expressed in the ax-
enic culture forms of the parasite are not the best targets 
for protective immunity. These failures have created a 
paradigm and led researchers to conclude that it would 
not be possible to generate an anti-T. cruzi vaccine. Over 
the past 10 years, we and others have challenged this te-
net by testing the hypothesis that non-antibody-mediat-
ed cellular immune responses to the antigens expressed 
in the mammalian forms of the parasites could indeed 
be used for the purpose of vaccination. Using a mouse 
model of the disease, we confirmed this hypothesis by 
inducing protective immunity against T. cruzi infection 
specifically mediated by CD4+ Th1 and CD8+ Tc1 cells 
specific for antigens expressed by trypomastigotes and 
amastigotes of T. cruzi. While it is possible to obtain 
protective immunity against a challenge with a homol-
ogous parasite strain, the strain variation observed in 
certain immunodominant epitopes may impose a severe 
restriction on the development and use of this method 
for mass vaccination.
This review is not aimed at describing a product that 
may never exist; instead, our intention is to demonstrate 
how to elicit immunity to T. cruzi prior to infection in 
experimental models.
CD4+ and CD8+ T cells are important factors in me-
diating host survival during T. cruzi infection
The innate and adaptive immunity induced by T. 
cruzi is tailored to allow the infection while prevent-
ing the death of the host. After contact with the para-
site, mammalian hosts initially undergo an acute phase 
of the infection, characterised by patient parasitemia. 
This period is critical for both the parasite and the host. 
The parasite has to concurrently establish a productive 
infection while at the same time keeping the host alive 
in order to maintain the parasite’s life cycle. After the 
acute phase, the host’s parasitemia levels decrease and 
the host progresses to the chronic phase of the infection. 
This latter phase is the period when most transmission 
to invertebrate hosts occurs. During the early stages 
of the acute phase, hosts survive because of strong in-
nate immunity, mediated mostly by Toll-like receptors 
through the activation of the adaptor molecule MyD88 
(Campos et al. 2004, Bafica et al. 2006, Bartholomeu 
et al. 2008). However, to avoid elimination, the parasite 
manages to significantly delay the onset of the CD8+ T 
cell-mediated immunity (CMI) response (Martin et al. 
2006, Tzelepis et al. 2006, 2007). This manoeuvre is 
critical for the parasite to establish the infection. Only 
after the parasitemia reaches a critical point is a power-
ful CD8+ T CMI response triggered, drastically reducing 
the parasitemia and securing host survival. This CD8+ T 
CMI response, and possibly the CD4+ T cells and anti-
bodies, collectively push the mouse into the long chronic 
phase of infection, during which the parasite is capable 
of transmission to the invertebrate host.
The role of T-cell-mediated adaptive immunity 
in the naturally acquired response to T. cruzi infec-
tion was determined by the use of genetically modi-
fied mice that express neither major histocompatibility 
complex (MHC) class I and II nor CD4 and CD8 mol-
ecules. These genetically deficient mouse strains are 
highly susceptible to acute infection because they are 
unable to control parasitemia (Rodrigues et al. 2003, 
Tarleton 2007). While MHC I- and CD8- deficient 
mice lack only CD8+ T CMI responses, MHC class II 
or CD4 deficiency leads to a more general failure, with 
reductions in both the antibody and the CD8 immune 
responses (Rottenberg et al. 1993, Tarleton 2007, Tzel-
epis et al. 2007). Therefore, CD4+ T cells may play an 
extremely important role in generating different mech-
anisms of protection. However, their function as an ef-
fector mechanism during naturally acquired immunity 
is less clear, as CD8-deficient mice are highly suscep-
tible to infection with most parasite strains (Tarleton 
2007, Tzelepis et al. 2007).
During human infection, T cells specific for T. cru-
zi can be detected in most individuals who are in the 
chronic phase of infection. Although it is difficult to 
definitively prove that these cells are important to host 
resistance, it is plausible that they exert an anti-parasitic 
effect similar to that seen in the mouse model of infec-
tion. During the chronic phase of the disease, most in-
dividuals have strong CMI to parasite antigens (Morato 
et al. 1986, Cetron et al. 1993, Dutra et al. 1996, Barros-
Mazon et al. 1997, Wizel et al. 1998b, Ribeirão et al. 
2000, Fonseca et al. 2005, Albareda et al. 2006, Alvarez 
et al. 2008). Events causing depression of CMI, such as 
immuno-suppressive treatment or HIV infection, lead to 
the relatively fast development of symptomatic forms of 
the disease in a percentage of chagasic patients (Rocha 
et al. 1994). In some cases, the reappearance of patient 
parasitemia characteristic of the acute phase of infection 
is observed (Sartori et al. 2002). This evidence suggests 
that CMI may help to maintain the low levels of parasites 
observed in chronic chagasic patients.
Characterization of the in vivo effector mechanisms 
mediated by protective T cells
Although there is evidence showing that T cells par-
ticipate in the protective immunity against experimen-
tal T. cruzi infection, the precise mechanism(s) used by 
these cells to eliminate T. cruzi has(ve) not been defined. 
The fact that T cells secrete IFN-γ suggests that this 
mechanism may play a role in eliminating intracellular 
forms of the parasite. IFN-γ is an important mediator of 
naturally-acquired immunity against the infection. Ge-
netically deficient mice that do not express the IFN-γ 
receptor or Stat4 are unable to control T. cruzi infection 
(Holscher et al.1998, Tarleton et al. 2000). However, no 
direct link between IFN-γ secretion by T cells and the in 
vivo anti-parasitic activity of these cells has been estab-
lished to date. 
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The IFN-γ-dependent mechanisms are in part medi-
ated by the production of nitric oxide (NO). In the ab-
sence of IFN-γ receptors, NO is not produced by mac-
rophages, suggesting that IFN-γ is the main inducer of 
NO synthase 2 (NOS2) activation. The evidence that NO 
is critical for eliminating T. cruzi during acute experi-
mental infection was obtained with genetically deficient 
mice that do not express NOS2. These animals are high-
ly susceptible to infection with different parasite strains 
(Holscher et al. 1998, Rodrigues et al. 2000).
In addition to producing IFN-γ, CD8+ T cells can lyse 
host cells infected with T. cruzi, or secrete other poten-
tially active mediators such as TNF-αa, granulisin or a 
number of different chemokines (Munoz-Fernandez et 
al. 1992, Aliberti et al. 1999, Stenger et al. 1999). In fact, 
CD8+ T cells specific for amastigote or trypomastigote 
antigens are capable of lysing non-phagocytic cells in-
fected with T. cruzi in vitro (Wizel et al. 1998b, Low et 
al. 1998). However, it is unclear whether lysis and DNA 
degradation of infected target cells by CD8+ T cells can 
be effective in restricting T. cruzi infection in vivo. Ge-
netically deficient mice that do not make perforin or 
granzyme B are not more susceptible to infection than 
wild-type mice after infection with the Brazil strain of T. 
cruzi (Kumar & Tarleton 1998). However, other T. cruzi 
strains behave differently and perforin-deficient mice 
are highly susceptible to infection (Tzelepis et al. 2006). 
Based on these observations, perforin-dependent and 
independent mechanism(s) provide resistance against T. 
cruzi infection in mice. The elucidation of the anti-par-
asitic mechanisms mediated by T. cruzi-specific CD8+ T 
cells will require further investigation using more com-
plex experimental models.
Target antigens of the protective immune response 
and design of recombinant subunit vaccines for ex-
perimental trials
T. cruzi antigens recognised by immune sera from 
immune or infected humans or animals were the first 
antigens to be described at the molecular level. This 
characterisation allowed researchers to conduct studies 
using recombinant proteins based on isolated, antigen-
specific genes. These isolated genes included members 
of the large trans-sialidase (TS) surface protein family 
expressed mainly in the infective trypomastigote and 
amastigote forms of the parasite. The second group 
of genes belonged to the family of cysteine-proteases 
(cruzipain) expressed in all of the different forms of the 
parasite. Other antigens formed a heterogeneous group 
including molecules such as the flagellar calcium-
binding protein, paraflagellar rod protein-2, LYT-1 an-
tigen, Ribosomal Protein L7a-Like Protein and KMP11, 
among others.
Several delivery antigens were used successfully to 
induce T. cruzi-specific T lymphocytes and protective im-
munity against an experimental infection. They included 
recombinant proteins mixed in the presence of distinct 
adjuvants, plasmid DNA and, more recently, recombi-
nant viruses and bacteria. Table displays a list matching 
the different antigens with their delivery system.
As shown in Table, protective immune response in 
the mouse model as measured by a reduction in acute 
phase parasitemia, tissue parasitism and mortality can 
be elicited by a variety of antigens using distinct deliv-
ery systems. In most cases, immunity elicited by these 
antigens is associated with type I immune response, gen-
erated by IFN-γ producing CD4+ and/or CD8+ T cells. In 
a few cases, some of the mechanisms of induction of pro-
tective immunity were investigated. Following intrana-
sal immunisation with (TS) in the presence of the TLR-9 
activator CpG ODN, B cells are critical to inducing type 
I immune response mediated by CD4+ and CD8+ T cells 
(Hoft et al. 2007). In this same model, the absence of 
CD4+ or CD8+ T cells also renders the vaccinated ani-
mals completely susceptible to infection. Because these 
animals were genetically deficient, these cells can be re-
quired for the induction or the effector phase of the im-
mune response, or both. Similarly, CD8- deficient mice 
failed to generate protection after immunisation with 
native Par-2 protein emulsified in CFA or recombinant 
adenovirus expressing TS or ASP-2 genes (Wrightsman 
et al. 2002, Machado et al. 2006).
The effector mechanisms responsible for the protec-
tive immunity have been evaluated in a few experimental 
models. Upon plasmid immunisation, depletion of either 
CD4+ or CD8+ T cells completely reversed protective im-
munity, thus demonstrating a non-overlapping role for 
these two subpopulations (Katae et al. 2002, Vasconce-
los et al. 2004). Following vaccination with recombinant 
protein of ASP-2 in alum and CpG ODN, only depletion 
of CD8+, but not CD4+, T cells reversed protective im-
munity (Araújo et al. 2005). Finally, by using a single 
T. cruzi epitope recognised by CD8+ T cells, Miyahira 
et al. (2005) elicited a protective immune response us-
ing a heterologous prime-boost strategy with recombi-
nant adenovirus and vaccinia virus. Although only a few 
experimental systems found type 1 CD4+ and CD8+ T 
cells to be necessary, these findings confirm the general 
paradigm that CD4+ and CD8+ T cells do play a key role 
in CMI. The question as to whether other cells types are 
also critical for the adaptive immunity induced by these 
recombinant vaccines requires additional investigation. 
In addition, it will be important to systematically define 
the phenotype and function of the specific T cells in or-
der to establish the immunological status of vaccinated 
individuals prior to their encounter with the pathogen. 
In spite of clear evidence that immunisation with T. 
cruzi antigens can provide protective immunity as mea-
sured by a reduction in acute phase parasitemia, tissue 
parasitism and mortality, it is not clear whether immu-
nisation will lead to either remission or a cure of the 
chronic phase symptoms of the disease. To determine 
the role of immunisation in reducing chronic phase dis-
ease symptoms, a number of experiments using different 
animal models must be performed. In many of the mod-
els described above, tissue inflammation and parasitism 
in the late chronic phase were significantly reduced fol-
lowing prophylactic vaccination (Garg & Tarleton 2002, 
Vasconcelos et al. 2004, Araújo et al. 2005). Therefore 
it is possible that prophylactic vaccinations indeed halt 
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the development of the chronic phase immunopatholo-
gies. Nevertheless, the most compelling evidence of a 
vaccine’s ability to reduce the immunopathology was 
obtained by therapeutic immunisation with T. cruzi 
genes encoding the TSA and Tc24 genes (Dunonteil et 
al. 2004). Whether these results are reproducible using 
different combinations of mouse and parasite strains re-
mains to be seen.
Evasion of T-cell immune responses
Viruses are the best known class of pathogens that 
use a variety of mechanisms to evade the immune rec-
ognition by MHC class I restricted CD8+ T cells. Some 
of these strategies may function at the level of antigen 
presentation by the infected cells such as: (i) downregu-
lation of MHC class I expression, (ii) interference with 
cytosolic proteolysis, (iii) inhibition of peptide trans-
port to the endoplasmic reticulum (ER), (iv) retention 
and destruction of MHC class I molecules in the ER 
and (v) presentation of mutant epitopes that do not bind 
to MHC I class molecules. Under these circumstances, 
infected cells have a limited amount of peptide/MHC-
class I complexes on their surface, making it difficult 
for them to be recognised by specific CD8+ T cells. A 
detailed review and examples of these evasion mecha-
nisms can be found in Antoniou and Powis (2008).
Alternatively, escape mechanisms can interfere with 
the recognition by MHC class I restricted CD8+ T cells. 
For example, mutant viruses can be selected with amino 
acid variations that retain binding to MHC class I mol-
TABLE
Summary of the different antigen delivery systems and the corresponding antigens used for experimental vaccination trials
against Trypanosoma cruzi infection
Delivery system Adjuvant T. cruzi antigen/gene Reference
Native protein alum and IL-12 Par-2 Wrightsman & Manning (2000)
Native protein CpG ODN Cruzipain Frank et al. (2003)
Rec. protein Anti-IL4/IL-12
MALP-2
Cruzipain Cruzipain Schnapp et al. (2002)
Cazorla et al. (2008)
Rec. protein Freunds adjuvant TS Fontanella et al. (2008)
Rec. protein CpG ODN TS Hoft et al. (2007)
Rec. protein Alum/CpG ODN ASP-2 Araújo et al. (2005)
de Alencar et al. (2007)
Plasmid DNA None TSA-1 Wizel et al. (1998a)
Dumonteil et al. (2004)
Zapata-Estrella et al. (2006)
Plasmid DNA IL-12 TSA Katae et al. (2002)
Miyahira et al. (2003)
Plasmid DNA None TS Costa et al. (1998).
Fujimura et al. (2001)
Hoft et al. (2007)
Plasmid DNA None ASP-1 Garg & Tarleton (2002)
Plasmid DNA None ASP-2 Garg & Tarleton (2002)
Boscardin et al. (2003)
Fralish & Tarleton
Vasconcelos et al. (2004)
Claser et al. (2007)
Plasmid DNA None ASP-3 Silveira et al. (2008)
Plasmid DNA None ASP-4 Silveira et al. (2008)
Plasmid DNA None CRP Sepulveda et al. (2000)
Plasmid DNA None KMP11 Planelles et al. (2001)
Plasmid DNA None Tc24 Dumonteil et al. (2004)
Plasmid DNA IL-12/GM-CSF TcG1 Bhatia & Garg (2008)
Plasmid DNA IL-12/GM-CSF TcG2 Bhatia & Garg (2008)
Plasmid DNA IL-12/GM-CSF TcG4 Bhatia & Garg (2008)
Rec. adenovirus None TS
ASP-2
Machado et al. (2006)
Machado et al. (2006)
Plasmid DNA + Rec. MVA None ASP-2 Dutra et al. (2009)
Rec. adenovirus + Rec. MVA None TSA Miyahira et al. (2005)
Rec. Salmonella None Cruzipain Cazorla et al. (2008)
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ecules but result in reduced recognition by T cells or 
generate antagonistic peptides that inhibit activation of 
specific T cells by the MHC-peptide complex (Ploegh 
1998, Antoniou & Powis 2008).
Most recently, the literature has described viral pro-
teins that interfere with the effector mechanisms medi-
ated by T cells. For example, poxviruses encode several 
soluble cytokine receptors that bind to and block the 
activity of IFN-α, β and γ, TNF-α, and IL-1. Also, pox-
viruses express a protein termed crmA that function-
ally inhibits Asp-specific cysteine proteases (caspases), 
therefore blocking apoptosis induced by CTL, TNF 
or Fas (Ploegh 1998). It is not known whether T. cruzi 
parasites have evolved to employ these immune evasion 
mechanisms. To date, not a single evasion mechanism 
has been confirmed in terms of a CD8+ T CMI response 
to T. cruzi. This lack of information most likely reflects 
the fact that the CD8+ T CMI response has not been thor-
oughly investigated.
Recently, the identification of CD8+ T cell epitopes 
derived against proteins of the TS superfamily allowed 
the comparison of the immunodominant responses re-
sulting from experimental infection in inbred mice fol-
lowing challenge with distinct parasite strains (Martin et 
al. 2006, Tzelepis et al. 2006, 2007, 2008). CD8+ T cells 
of a single mouse strain (C57BL/6 mice) infected with 
different parasite strains recognised distinct peptides 
as the immunodominant epitope. The diversity of the 
immunodominant response between strains presents a 
significant challenge for developing vaccines. A vaccine 
would require a number of CD8+ epitopes that cover not 
only the different human MHC haplotypes but also the 
different parasite strains. Alternatively, the use of sub-
dominant epitopes could favour the protective immune 
responses without requiring so many epitopes (Rodri-
gues et al. 2009).
Finally, the presence of a strong CD8+ T cell immune 
response may select variants that no longer act as a target 
for these protective CD8+ T cells as is the case with HCV 
or HIV (Tester et al. 2005, Watkins 2008). This hypoth-
esis was tested once following vaccination with TS in the 
presence of CpG ODN. Parasites isolated from immune 
mice did not show any increase in resistance to anti-TS 
immune responses, indicating that antigenically distinct 
forms of the parasites were not selected by the strong pro-
tective immune response (Hoft et al. 2007). The ques-
tion as to whether the absence of selectively imposed 
variations has an effect on CD8+ T cell immune evasion 
should be evaluated in more experimental models.
Perspectives
The knowledge that T cells are essential for efficient 
immunity to T. cruzi has raised important questions with 
basic and applied implications. Several gaps in our basic 
knowledge are expected to be filled in the years to come. 
Some of the most relevant questions are: (i) how are spe-
cific CD8+ T cells induced and maintained in vivo? (ii) 
What are the main effector mechanisms operating in 
vivo against the different forms of the parasite? (iii) Are 
there specific or general mechanisms of immune evasion 
used by each strain? These questions are even more rel-
evant and much more complex and difficult to study in 
humans due to the obvious technical limitations.
From the applied point of view, it is now clear that 
a number of different delivery systems can be efficient 
in terms of the expansion of protective T lymphocytes. 
Vaccination trials using non-human primates aimed at 
inducing T CMI have yet to be conducted and should 
provide important information about the feasibility of 
this strategy to develop the first vaccines against T. 
cruzi infection.
It is possible that these studies on the immune re-
sponse elicited following vaccination with recombinant 
proteins may contribute to the development of new strat-
egies for the prevention or treatment of T. cruzi infec-
tion. However, due to the complex nature of this para-
sitic disease, we believe that it is too early to anticipate 
the utility of this strategy in humans.
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